CLINICAL TRIALS PROFILE FOR DEUCRAVACITINIB
✉ Email this page to a colleague
All Clinical Trials for deucravacitinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03920267 ↗ | Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus | Recruiting | Bristol-Myers Squibb | Phase 2 | 2019-03-26 | The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE). |
| NCT03934216 ↗ | Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis | Active, not recruiting | Bristol-Myers Squibb | Phase 2 | 2019-07-01 | The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC). |
| NCT04036435 ↗ | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis | Recruiting | Bristol-Myers Squibb | Phase 3 | 2019-08-12 | The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study. |
| NCT04536961 ↗ | A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants | Completed | Bristol-Myers Squibb | Phase 1 | 2020-09-10 | The purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants. |
| NCT04671953 ↗ | Effect of BMS-986165 on the Blood Levels of Metformin | Completed | Bristol-Myers Squibb | Phase 1 | 2020-12-18 | The purpose of this study is to investigate the effects of BMS-986165 on the drug levels of metformin in healthy participants. |
| NCT04908189 ↗ | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor | Recruiting | Bristol-Myers Squibb | Phase 3 | 2021-07-15 | The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment. |
| NCT04908202 ↗ | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs | Recruiting | Bristol-Myers Squibb | Phase 3 | 2021-07-13 | The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for deucravacitinib
Condition Name
Clinical Trial Locations for deucravacitinib
Trials by Country
Clinical Trial Progress for deucravacitinib
Clinical Trial Phase
Clinical Trial Sponsors for deucravacitinib
Sponsor Name
